Literature DB >> 30095979

Immune Checkpoint Inhibitor-related Pneumonitis. Incidence, Risk Factors, and Clinical and Radiographic Features.

Rebecca Sternschein1, Matthew Moll1, Julie Ng1, Carolyn D'Ambrosio1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30095979      PMCID： PMC6835075          DOI： 10.1164/rccm.201803-0525RR

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  16 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 2.  Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Authors:  Monica Khunger; Sagar Rakshit; Vinay Pasupuleti; Adrian V Hernandez; Peter Mazzone; James Stevenson; Nathan A Pennell; Vamsidhar Velcheti
Journal:  Chest       Date:  2017-05-10       Impact factor: 9.410

Review 3.  Pulmonary Toxicities from Checkpoint Immunotherapy for Malignancy.

Authors:  Jennifer D Possick
Journal:  Clin Chest Med       Date:  2017-06       Impact factor: 2.878

4.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

Authors:  Jeffrey S Weber; Sandra P D'Angelo; David Minor; F Stephen Hodi; Ralf Gutzmer; Bart Neyns; Christoph Hoeller; Nikhil I Khushalani; Wilson H Miller; Christopher D Lao; Gerald P Linette; Luc Thomas; Paul Lorigan; Kenneth F Grossmann; Jessica C Hassel; Michele Maio; Mario Sznol; Paolo A Ascierto; Peter Mohr; Bartosz Chmielowski; Alan Bryce; Inge M Svane; Jean-Jacques Grob; Angela M Krackhardt; Christine Horak; Alexandre Lambert; Arvin S Yang; James Larkin
Journal:  Lancet Oncol       Date:  2015-03-18       Impact factor: 41.316

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

Authors:  Julie R Brahmer; Scott S Tykodi; Laura Q M Chow; Wen-Jen Hwu; Suzanne L Topalian; Patrick Hwu; Charles G Drake; Luis H Camacho; John Kauh; Kunle Odunsi; Henry C Pitot; Omid Hamid; Shailender Bhatia; Renato Martins; Keith Eaton; Shuming Chen; Theresa M Salay; Suresh Alaparthy; Joseph F Grosso; Alan J Korman; Susan M Parker; Shruti Agrawal; Stacie M Goldberg; Drew M Pardoll; Ashok Gupta; Jon M Wigginton
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

Review 7.  Toxicities of Immunotherapy for the Practitioner.

Authors:  Jeffrey S Weber; James C Yang; Michael B Atkins; Mary L Disis
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

Review 8.  PD-1 and PD-1 ligands: from discovery to clinical application.

Authors:  Taku Okazaki; Tasuku Honjo
Journal:  Int Immunol       Date:  2007-07-02       Impact factor: 4.823

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 10.  PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.

Authors:  Jiaying Wu; Dongsheng Hong; Xiangnan Zhang; Xiaoyang Lu; Jing Miao
Journal:  Sci Rep       Date:  2017-03-08       Impact factor: 4.379
View more
  1 in total

Review 1.  Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.

Authors:  Juwhan Choi; Sung Yong Lee
Journal:  Immune Netw       Date:  2020-02-17       Impact factor: 6.303
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.